Nanobiotix S.A. (Euronext: NANO, NASDAQ: NBTX), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches for cancer and other serious diseases, announced its participation in three major investor conferences during the week of November 10, 2025. The company’s executive team, including CEO Laurent Levy and CFO Bart van Rhijn, will lead presentations at the UBS Global Healthcare Conference, Guggenheim Healthcare Innovation Conference, and Stifel Healthcare Conference. These engagements underscore Nanobiotix’s strategic visibility among global investors and reinforce its leadership in nanomedicine innovation.
Science Significance
Nanobiotix continues to shape the scientific frontier of nanotherapeutics, leveraging its proprietary physics-based platforms to enhance the precision and efficacy of cancer treatments. The company’s participation in these high-profile conferences reflects the increasing recognition of NBTXR3, its lead radioenhancer candidate designed to improve radiotherapy outcomes across solid tumors. With more than 25 patent families spanning oncology, bioavailability, and central nervous system disorders, Nanobiotix exemplifies the integration of nanotechnology with clinical oncology, translating foundational science into impactful medical solutions.
Regulatory Significance
While these presentations are primarily for investors, they come at a pivotal stage in Nanobiotix’s late-clinical development trajectory, following ongoing Phase III studies and active engagement with global regulators. The company’s U.S. and European presence underscores its ability to navigate dual regulatory pathways, ensuring that its technologies meet FDA and EMA compliance standards. Such cross-regional activity enhances transparency and stakeholder confidence in Nanobiotix’s commitment to rigorous regulatory science and patient safety.
Business Significance
Advertisement
Participation in the UBS, Guggenheim, and Stifel conferences places Nanobiotix at the center of biotech capital markets and strategic partnerships. These investor interactions enable the company to showcase its nanotherapy pipeline, discuss commercial readiness, and highlight potential collaboration or licensing opportunities. CFO Bart van Rhijn and CEO Laurent Levy will articulate the company’s roadmap for advancing its proprietary nanophysics platforms, fostering investor trust, and attracting long-term partnerships vital for commercialization and sustained growth in the oncology innovation space.
Patients’ Significance
For patients, the science behind Nanobiotix’s nanotherapeutics translates into potentially transformative outcomes. Its approach aims to amplify the tumor-killing effects of radiotherapy while minimizing harm to surrounding healthy tissue—a key limitation of conventional cancer treatment. As the company advances late-stage trials, these innovations could soon provide new therapeutic options for patients with head and neck cancers and other solid tumors where treatment resistance remains a major clinical challenge. Nanobiotix’s work represents a tangible step toward personalized, less toxic, and more effective cancer care.
Policy Significance
The company’s dual listings on Euronext Paris and NASDAQ exemplify the internationalization of biotech innovation and capital flow. Nanobiotix’s progress underscores the importance of transatlantic regulatory alignment and public–private collaboration in advancing high-impact technologies like nanomedicine. The firm’s scientific achievements support broader health policy goals aimed at reducing cancer mortality, fostering advanced materials science, and encouraging public investment in next-generation therapeutic platforms. Its continued engagement with investors helps align science-driven innovation with policy-backed healthcare transformation.
By participating in multiple leading healthcare conferences, Nanobiotix continues to expand its global profile as a trailblazer in nanotherapeutic oncology. Its innovative platforms, robust patent portfolio, and transatlantic regulatory strategy reflect a maturing biotech poised to redefine how radiotherapy and nanotechnology intersect to fight cancer. These investor presentations mark not only a business milestone but also a reaffirmation of Nanobiotix’s commitment to advancing science that saves lives and to positioning nanomedicine at the forefront of modern oncology.
Source: Nanobiotix S.A. press release
